Roche Sees Cancer Combos Start To Deliver
Executive Summary
Roche presented a strong second quarter and was able to highlight a positive debut of Tecentriq, its PD-L1 antagonist, which brought the Swiss group into the lauded programed-death checkpoint inhibitor field.
You may also be interested in...
ESMO Preview: Opdivo Under Pressure
All eyes will be on beleaguered Opdivo at ESMO 2016 as BMS's leading checkpoint inhibitor comes under scrutiny in the NSCLC and renal cell cancer space. Details of Merck & Co's KEYNOTE-024 trial, Roche's Tecentriq in lung cancer and Exelixis' cabozantinib in kidney cancer could impact on how Opdivo's prospects are viewed.
Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal
After a series of blockbuster licensing deals last year, South Korea’s Hanmi has struck another major alliance, this time licensing out a novel oral RAF inhibitor that will strengthen biosimilar-threatened Genentech’s oncology portfolio.
Roche Raises IO Credentials On Tecentriq Lung Cancer Data
With positive overall survival data from the Phase III OAK trial of Tecentriq in non-small cell lung cancer, Roche enters the top flight of immuno-oncology companies alongside Merck and Bristol-Myers Squibb.